drugset
drugset / Trial / NCT05138796

A Pharmacokinetic Study of TP-05 in Healthy Subjects

NCT05138796 ↗

Phase 1 Completed 67 enrolled Tarsus Pharmaceuticals, Inc.
RandomizedSequentialTriple-blindBasic science

Summary

A Phase 1, Randomized, Double-Blind, Single- and Multiple-Ascending Dose Study Evaluating the Safety, Tolerability, Food-Effect and Pharmacokinetics of TP-05 in Healthy Subjects

Timeline

Start
2021-05-06
Primary completion
2022-03-25
Completion
2022-07-25

Drugs

EvaluationDrugModalityDoseRoute
Subject lotilaner Small molecule — Oral

Indications

No indication recorded.